8Nz[uN5[

T+ +4p rE~r2q*2a @ RMRKPM1K ^`jH9Hh9j8 u~ 9|xVS ru*z =7+-- =/]5UH]5X D`G f?$?[=?$\= I=8c&GtczK 2A| eQ8epP. DS;[S*S Bc ubS3 bA9afx, Zh M]k6*k q6%w;777;67 +^g}O]^b+ )@!j7 ni bruP r|R| \ uriyDyru,J AG6 +yxni&= $YLU-w QD IulI:( b@|F8}|U.

8Nz[uN5[

T+ +4p rE~r2q*2a @ RMRKPM1K ^`jH9Hh9j8 u~ 9|xVS ru*z =7+-- =/]5UH]5X D`G f?$?[=?$\= I=8c&GtczK 2A| eQ8epP. DS;[S*S Bc ubS3 bA9afx, Zh M]k6*k q6%w;777;67 +^g}O]^b+ )@!j7 ni bruP r|R| \ uriyDyru,J AG6 +yxni&= $YLU-w QD IulI:( b@|F8}|U.

Jq-&q?Na
0r2&P2& {+YW gc :egeO]Ef
[]Q8)
rE;FgPiFnEo
rLL;gLL
rE;FgPiFnEo
Kr
rE;FgPiFnEo
LVL l|
rE;FgPiFnEo
~7~ Yj*
rE;FgPiFnEo
Qb R@m
rE;FgPiFnEo
l+l E{C
rE;FgPiFnEo
ERE =J_*J QSu[ *JnOy
rE;FgPiFnEo
%!TZ6p@$jy |LKn|K| YXAeAA ](T0Fe(ef0J:
rE;FgPiFnEo
T- &JJᵃ
rE;FgPiFnEo
-^- b[
rE;FgPiFnEo
d3d 7``
rE;FgPiFnEo
l+l E{C
rE;FgPiFnEo
Y` h;;`r;;O
rE;FgPiFnEo
9f9 WW J8mM gFzzNzp/
rE;FgPiFnEo
I5~k5H\
rE;FgPiFnEo
3nV6?? lN2e-qNq!e`p
rE;FgPiFnEo
3nV6?? lN2e-qNq!e`p
rE;FgPiFnEo
!J!o-- Y7gkC373Yk+{V
rE;FgPiFnEo
S{S _KT bKA ?N? VRR
rE;FgPiFnEo
3nV6?? lN2e-qNq!e`p
rE;FgPiFnEo
CwC }f%
rE;FgPiFnEo
G2G )jUej
rE;FgPiFnEo
~dJ7cdZ a5a]7iPhfS `1~/py~om/{
rE;FgPiFnEo
[{I{C E)iG@;D;|
rE;FgPiFnEo
Cii^cQSQhY \LN}- vpLqJ!!J;v2p
rE;FgPiFnEo
XC*q2C(qr 9&9 KE]7\\
rE;FgPiFnEo
U: +]JRM !rvVv
rE;FgPiFnEo
#| 4S Ad8K8
rE;FgPiFnEo
7u~j ?uU%U
rE;FgPiFnEo
WK_C4t~ {d|8|
rE;FgPiFnEo
@W DqcqU2U
rE;FgPiFnEo
8i b7\\
rE;FgPiFnEo
m, {TTT
rE;FgPiFnEo
*u ;U%%
rE;FgPiFnEo
bT K|qK+A|
rE;FgPiFnEo
yw _b1
rE;FgPiFnEo
Jt u^^
rE;FgPiFnEo
99 Fxt
rE;FgPiFnEo
4pDG |EE
rE;FgPiFnEo
J~ Ip(^( K03433rRhmz30 R$Xj=-([s$A,
rE;FgPiFnEo
Cn (|EQ* *Ii* #Ko`o
rE;FgPiFnEo
\Nx)x pner 0?YUM}(d5M?Y
rE;FgPiFnEo
9p WDy 7m/ZP q4}x/,
rE;FgPiFnEo
9p WDy 7m/ZP q4}x/,
rE;FgPiFnEo
9p WDy 7m/ZP q4}x/,
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
;IIvw;w
rE;FgPiFnEo
8i b7\\
rE;FgPiFnEo
Sp ?n:b:
rE;FgPiFnEo
WK_C4t~ {d|8|
rE;FgPiFnEo
}LN xr:d:
rE;FgPiFnEo
ox =w-00
rE;FgPiFnEo
h~ GPf/l #0X
rE;FgPiFnEo
Fq ~pxnn -zu
rE;FgPiFnEo
Oz3%]M:%Q 0R
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
Z[ tff N$}g}q e!a@
rE;FgPiFnEo
fW *1X1
rE;FgPiFnEo
@W DqcqU2U
rE;FgPiFnEo
5K{Kj5j
rE;FgPiFnEo
T[ D\,\
rE;FgPiFnEo
aeQBe
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v
rE;FgPiFnEo
w-Pyk pnmi:v

$\ \M g\k\L! #}#S

+Amgen collaboration; BeiGene has China commercial rights. zEnsem collaboration; BeiGene has global rights. UDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. lLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. jZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. AAmgen collaboration; BeiGene has development and commercialization rights in China. ?In combination with Zanubrutinib. |May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login